The Device

Saving sight sooner makes
brighter futures

How it works
In a normal eye, light passes through the lens with the focal point correctly reaching the back of the eye, known as the retina.   

As myopia progresses, the eye’s axial length increases, which means that the focal point of light entering the eye falls in front of the retina.  Continued axial lengthening and further focal point misalignment leads to high myopia.   

The Eyerising Myopia Management Device delivers repeated low-level red-light therapy to the back of the eye, where it stimulates blood flow and thickens the layer of the back of the eye known as the choroid. This helps to slow further elongation of the eye’s axial length and thereby control myopia progression.  

Eyerising Myopia Management device
RLRL technology

3 minutes, 2 times per day, 5 days per week

Achieves up to 87.7% myopia control efficacy7
An extensive clinical trial program has proven the effectiveness of RLRL therapy and the Eyerising Myopia Management Device for the treatment of myopia.   

In our landmark trial, our device was shown to achieve up to 87.7% myopia control efficacy when a patient was over 75% compliant to the treatment protocol. Children on RLRL therapy for 1 year had a 76.6% reduction in myopia progression overall compared to those who just wore spectacles. Children who continued RLRL therapy for a second year then had a 75% reduction in myopia progression compared to those who switched to glasses in the second year.  

To find out more or to obtain copies of some of our key scientific publications, please visit the Science Hub or contact us on: info@eyerisinginternational.com

A powerful new addition to your myopia toolkit

As the device is non-invasive and has a wide age range availability, it offers an opportunity to start treatment earlier and in children who are not willing to use or compliant with eye drops or contact lenses. Additionally, there is the option of using RLRL not only as standalone therapy but as adjunct therapy, where it has shown strong efficacy in patients not responding to conventional myopia treatments such as orthokeratology2.

  RLRL cannot be used in conjunction with atropine. Patients need to stop using atropine for 2 weeks prior to starting RLRL therapy.

With its simple protocol (3 minutes, twice daily, 5 days a week) and ease-of-use via a touchscreen, it can be used by children as young as 3 years of age, who can use the device under parental or guardian supervision.  

Furthermore, the device monitors and shares patient compliance data with parents, guardians and medical practitioners for use during follow-up examinations, especially as it has been proven that higher compliance is associated with higher treatment efficacy1, giving both parents and practitioners ease of mind as to the treatment effect.  

No drugs

No injections

No contact lenses

Frequently asked questions

Prescribing the device
‍
How many years do you prescribe the Eyerising Myopia Management Device for?
The goal of myopia management is to control or stabilise its progression and prevent the incidence of high myopia. Younger children may need myopia management for a longer time, and teenagers may require it for a shorter time. Our device has clinical evidence for up to 2 years continuous usage at the moment, with 3 year data pending. The shelf life of the device itself is 5 years.  
‍
What happens when a child stops using the therapy?
Abrupt discontinuation of RLRL is not recommended. Instead, it is recommended that you taper the treatment gradually, or consider starting them on alternative treatments if their myopia is still progressing. We also recommend to get their eyes checked routinely (every 6 months), or more frequently if indicated by their myopia progression. For more information on our tapering protocol, please contact info@eyerisinginternational.com.  
 
What are the side effects to look our for?
The commonest side effect observed is afterimage, where the child can still see the red light or some form of light in their vision after treatment. This typically disappears within a few minutes, and we recommend the child close their eyes during this time. If the afterimage lasts longer than 5 minutes, please stop using the device and seek advice from an eye care professional. The afterimage should gradually reduce in duration and disappear with repeated use.   Other side effects may include glare and flash blindness. If side effects persist, or there are any changes to a child’s visual acuity, please advise patients to stop using the device and seek advice from an eye care professional.  
‍
How frequently should patents on RLRL be seen in clinic?
We recommend to schedule clinic appointments at 1 month, 3 months, 6 months and every 6 months after to monitor the progression of your patient’s myopia and response to the therapy.   For more information on recommended examinations and our full treatment protocol, please contact info@eyerisinginternational.com.  
‍
Can RLRL be combined with other myopia treatments?
Yes, RLRL can be used in conjunction with orthokeratology lenses, soft contact lenses (e.g. MiSight) and specially designed glasses (e.g. Miyosmart). However, RLRL cannot be used in conjunction with atropine (e.g. Myopine). Children on atropine must stop for a 2-week washout period prior to commencing RLRL therapy.  
‍
Is the Eyerising device safe for retinal exposure?
The safety of laser products for the eye depends on various factors, including their power, distance from the eye, size of the beam and duration of exposure. The laser in the Eyerising Myopia Management Device is a low-level laser, with a power far lower than lasers used in other medical settings. Our device has undergone rigorous testing which confirmed that it meets the appropriate laser safety standards. For more information, please visit the Device Safety page or contact us at: info@eyerisinginternational.com  

‍Using the device  
‍
How often do you need to use the device?
You should use the device twice a day for 5 days a week, which means 10 times a week in total. It is very important to follow this recommendation, as our clinical trial showed that higher compliance results in higher efficacy. There must also be a 4-hour interval between sessions on the same day. Of note, our device is able to monitor each session, therefore patients are unable to repeat sessions within their 4-hour interval or administer more than 10 sessions in 7 days.  
‍
Do you need to use the device at the same time each day or on the same day each week?
No, you can use the device at any time during the day and on any 5 days during the week. However, there must be at least a 4-hour interval between two sessions on the same day. We recommend using the device from Monday to Friday and taking the weekends off, as it may be easier to fit the treatment into the child’s school schedule (once before school and once after school) and form a habit.  

Do you still need wear glasses?
Yes, children on RLRL will still need to wear glasses in order to get corrected vision during the day. Studies have shown that children are more likely to have a higher myopia progression rate when their vision remains uncorrected.  Of note, this excludes the use of RLRL in premyopia, which has been investigated in several studies. For more information, please visit our Science Hub.  
‍
What happens if you have to travel and cannot bring the device with you?
We understand that it may be difficult to bring the device with you on holiday. If a child misses a few days of treatment as a result, for example within a week, this should not cause any issues. However, we do recommend bringing the device with you if possible, especially for longer trips.    
‍
What do we advise children do before and during the session?
Make sure the child takes off their glasses or removes their contact lenses during the treatment session. It is also mandatory for the child to keep their eyes open during the session, although they can still blink as normal.   In the first session, the parent or guardian should help the child to adjust the interpupillary distance via the interpupillary distance adjustment knob, in order to make the two red dots merge into one dot. If this is not possible, adjust to make sure the red light is as bright as possible.  

What do we advise parents in order to optimise treatment results?
Our clinical studies have shown that better compliance means better treatment efficacy. It is important to advise parents to help encourage their children to use the device regularly and form a habit in the first few weeks.  
For the first week, we recommend parents to record the duration of any afterimage after each session. If the afterimage is longer than 5 minutes, they should be advised to please stop using the device and contact an eye care professional.

References

1. Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, Wong TY, Naduvilath TJ, Resnikoff S. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology. 2016 May;123(5):1036-42. Doi: 10.1016/j.ophtha.2016.01.006. Epub 2016 Feb 11. PMID: 26875007.
2. Mehta, N. and Wen, A. (2019) Myopia: A global epidemic, Retina Today. Available at: https://retinatoday.com/articles/2019-sept/myopia-a-global-epidemic (Accessed: 12 March 2024). 
3. Ruiz-Pomeda A, Pérez-Sánchez B, Valls I, et al. MiSight Assessment Study Spain (MASS). A 2-year randomized clinical trial. Graefes Arch Clin Exp Ophthalmol. 2018;256(5):1011-1021.
4. Eyenovia enrolls first patient in phase III CHAPERONE Study for progressive myopia [news release]. New York: Globe Newswire; June 4, 2019. https://www.globenewswire.com/news-release/2019/06/04/1863931/0/en/Eyenovia-Enrolls-First-Patient-in-Phase-III-CHAPERONE-Study-for-Progressive-Myopia.html. Accessed June 25, 2019.
5. Lam CSY, Tang WC, Tse DY, et al. Defocus incorporated multiple segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial [published online ahead of print May 29, 2019]. Br J Ophthalmol. Doi: 10.1136/bjophthalmol-2018-313739.
6. Singapore National Eye Centre, Singapore Eye Research Institute, and Johnson & Johnson Vision set sights on halting global myopia epidemic [news release]. Singapore: PRNewswire; November 12, 2018. https://www.prnewswire.com/news-releases/singapore-national-eye-centre-singapore-eye-research-institute-and-johnson–johnson-vision-set-sights-on-halting-global-myopia-epidemic-300747895.html. Accessed June 25, 2019.
7. Jiang, Yu, et al. “Effect of repeated low-level red-light therapy for myopia control in children: a multicenter randomized controlled trial.” Ophthalmology 129.5 (2022): 509-519.

navigation

We acknowledge the Wurundjeri Woi Wurrung people as the Traditional Owners of the land on which our offices are situated, and pay our respects to their Elders, past, present, and emerging.